Monday, December 12, 2022 12:31:07 PM
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, in addition to the exercise in full of the underwriters' option to purchase an additional 3,146,853 shares of common stock. The gross proceeds from the exercise of the overallotment option were $9 million, bringing the total gross proceeds to ADMA from the offering to $69 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
ADMA intends to use the net proceeds from this offering to accelerate commercialization and production activities, complete plasma center buildout and obtain FDA approvals, to conclude post FDA marketing approval research and development projects, and for working capital, capital expenditures and for general corporate purposes.
Raymond James & Associates, Inc., Cantor Fitzgerald & Co. and Mizuho Securities USA LLC acted as joint book-running managers of the offering.
The offering of the securities described above was made by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-256643) previously filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on August 3, 2021. The final prospectus supplement, including the accompanying prospectus, relating to the offering was filed with the SEC on December 7, 2022 and is available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at prospectus@cantor.com, or from Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020, by email at US-ECM@us.mizuho-sc.com, or by telephone at (212) 205-7600.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
Recent ADMA News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:05:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 03/11/2024 04:19:55 PM
- ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM® • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:00:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:05:30 PM
- ADMA Biologics to Participate in the Raymond James Institutional Investor Conference • GlobeNewswire Inc. • 03/05/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 02:00:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:00:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:00:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:00:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:00:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:00:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:00:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:21:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:15:33 PM
- ADMA Biologics Announces CFO Transition • GlobeNewswire Inc. • 02/28/2024 09:10:00 PM
- ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 02:00:25 AM
- ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 • GlobeNewswire Inc. • 02/21/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 01:00:18 PM
- ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 04:50:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:30:30 PM
- ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM